Last reviewed · How we verify
Systane Complete PF
Systane Complete PF is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms.
Systane Complete PF is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms. Used for Dry eye disease / Keratoconjunctivitis sicca.
At a glance
| Generic name | Systane Complete PF |
|---|---|
| Sponsor | University of California, Berkeley |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This preservative-free (PF) formulation combines multiple lubricating agents including glycerin, propylene glycol, and mineral oil to provide sustained moisture and protection to the cornea and conjunctiva. The multi-component formulation mimics natural tear composition to reduce friction, improve tear film stability, and provide relief from dry eye discomfort.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Ocular irritation
- Blurred vision
- Eye discomfort
Key clinical trials
- Subjective and Objective Performance of Systane Complete Multi-Dose PF Versus Walgreen's Lubricant Balance (PHASE4)
- Artificial Tears, Tear Lipids and Tear Film Dynamics (PHASE4)
- Comparative Efficacy Study to Demonstrate the Non-inferiority of I-DROP® MGD Versus 2 Competitor Eye Drops in Managing Evaporative Dry Eye (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Systane Complete PF CI brief — competitive landscape report
- Systane Complete PF updates RSS · CI watch RSS
- University of California, Berkeley portfolio CI